Antibody engineering technology company Creative Biolabs has formed a strategic expansion of its next-generation bioconjugate (xDC) development services.
As the oncology drug pipeline faces unprecedented target saturation, industrial R&D teams are actively seeking sophisticated molecular architectures that offer superior selectivity, accelerated internalisation, and diversified mechanism of actions (MoAs). Creative Biolabs’ expanded platform directly addresses these market mandates by bridging advanced antibody design with precision chemical synthesis.
Overcoming target saturation: Next-gen bispecific ADC (BsADC) engineering
Traditional monoclonal antibody-based ADCs often struggle with poor tumor penetration, low internalisation rates, and acquired resistance. Creative Biolabs’ customised BsADC platform offers two distinct architecture tracks to break through these physiological barriers:
Fast-internalising receptor-based BsADCs: Utilising a dual-targeting approach where one arm binds a highly specific tumor-surface antigen and the secondary arm hitches a ride on a fast-internalising receptor (e.g., PRLR, HER2). This dual-mechanism actively drags the entire therapeutic complex into the lysosomal compartment for rapid, high-efficiency payload release.
Biparatopic receptor-based BsADCs: Simultaneously targeting two non-overlapping, distinct epitopes on the same tumor antigen. This strategic multi-epitope engagement induces receptor clustering, cross-linking, and enhanced lysosomal trafficking, drastically improving the therapeutic window against low-to-moderate antigen-expressing solid tumors.
Expanding the payload frontier: precision antibody-oligonucleotide conjugate (AOC) platforms
Beyond small-molecule chemotherapeutic toxins, the biopharma industry is shifting toward gene-level modulation. However, the systemic delivery of nucleic acid therapies (siRNA, ASO) has been historically restricted by liver-centric clearance and blood-brain barrier (BBB) blockades.
Creative Biolabs’ AOC development platform serves as the premier targeted delivery vehicle for genetic medicines:
Accessing undruggable tissue types: By leveraging high-affinity monoclonal antibodies as navigation units, AOCs can selectively transport oligonucleotides into complex physiological spaces, including the central nervous system (CNS) and tumor micro-environments.
Advanced site-specific conjugation chemistries: To guarantee strict batch-to-batch consistency and optimal Drug-to-Antibody Ratios (DAR), the platform supports precise amine conjugation, reduced sulfhydryl (thiol) conjugation, and site-directed carbohydrate conjugation within the Fc region to minimize steric hindrance.
A one-stop ADC base from concept to CMC readiness
A successful xDC therapeutic relies heavily on the synergy between its components. Creative Biolabs provides industrial clients with a holistic, modular workflow that mitigates development risks across the entire pre-clinical cycle:
Antibody discovery & optimisation: Target validation, dual-arm screening, and engineering of internalizing variants.
Custom Linker-Payload Synthesis (DrugLnk): Specialised design of pH-sensitive, disulfide, peptide, and non-cleavable linkers paired with diverse functional warheads.
Comprehensive In Vitro & In Vivo evaluation: Leveraging advanced 3D spheroid cell culture models for tissue penetration analysis, alongside precision pharmacokinetics (PK), safety assessment, and bystander killing evaluations.
“Modern biopharma innovation requires moving beyond standard drug templates,” stated a senior scientist at Creative Biolabs. “Our mission is to provide industrial clients with the precise bio-conjugation architecture and engineering depth required to turn highly complex molecular concepts—whether it’s a biparatopic bispecific ADC or a CNS-targeted AOC—into robust, scalable, and clinically viable therapeutic pipelines.”
